Log In
BCIQ
Print this Print this
 

danoprevir (ASC08, ITMN-191, RG7227) (formerly R7227)

Also known as: formerly ITMN B

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat chronic HCV genotype 1 infection in treatment-naïve patients; Treat HCV genotype 1 infection; Treat HCV genotype 1 infection in patients who failed previous therapy; Treat HCV infection
Regulatory Designation
PartnerAscletis Pharmaceuticals Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/22/2013

Undisclosed

0

Undisclosed

Get a free BioCentury trial today